Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS12010 capsules in moderate-to-severe rheumatoid arthritis (Phase II, randomized, double-blind, placebo-controlled)
CTR20260215Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QLS12010 in rheumatoid arthritis (RA) (4 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Change from baseline in DAS28-CRP at week 12. Started Mar 2026; status: active.
02
Drugs
QLS12010
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20260215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260215.